Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (611-620 of 724) with videos related to

Pageof 73
Sort By:
Hormones & Cancer|May 23, 2014
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialAntonio M Lerario, Francis P Worden, Carole A Ramm, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
The Lancet. Child & Adolescent Health|September 14, 2019
Neurodevelopment of HIV-exposed uninfected children in South Africa: outcomes from an observational birth cohort studyCatherine J Wedderburn, Shunmay Yeung, Andrea M Rehman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2025
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell CarcinomaRohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, et al.
BJU International|November 8, 2008
FYN is overexpressed in human prostate cancerEdwin M Posadas, Hikmat Al-Ahmadie, Victoria L Robinson, et al.
The European Respiratory Journal|November 23, 2018
Intra-breath measures of respiratory mechanics in healthy African infants detect risk of respiratory illness in early lifeDiane M Gray, Dorottya Czovek, Lauren McMillan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignanciesChristine M Hartford, Apurva A Desai, Linda Janisch, et al.
Cell Death & Disease|October 24, 2019
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cellsVinay Sagar, Rajita Vatapalli, Barbara Lysy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Pageof 73

Showing results (611-620 of 724) with videos related to

Sort By:
Pageof 73
Hormones & Cancer|May 23, 2014
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialAntonio M Lerario, Francis P Worden, Carole A Ramm, et al.
Cancer|May 5, 2020
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO studyTanguy Y Seiwert, Sara Kochanny, Kevin Wood, et al.
The Lancet. Child & Adolescent Health|September 14, 2019
Neurodevelopment of HIV-exposed uninfected children in South Africa: outcomes from an observational birth cohort studyCatherine J Wedderburn, Shunmay Yeung, Andrea M Rehman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2025
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell CarcinomaRohan R Katipally, Greeshma Rajeev-Kumar, Abhishek A Solanki, et al.
BJU International|November 8, 2008
FYN is overexpressed in human prostate cancerEdwin M Posadas, Hikmat Al-Ahmadie, Victoria L Robinson, et al.
The European Respiratory Journal|November 23, 2018
Intra-breath measures of respiratory mechanics in healthy African infants detect risk of respiratory illness in early lifeDiane M Gray, Dorottya Czovek, Lauren McMillan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignanciesChristine M Hartford, Apurva A Desai, Linda Janisch, et al.
Cell Death & Disease|October 24, 2019
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cellsVinay Sagar, Rajita Vatapalli, Barbara Lysy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Pageof 73